Fig. 1From: A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effectsTherapy strategy with DC-CIK cells+anti-CTLA-4 nanobodies. DC-CIK cells were first generated. Then, the nanobodies against CTLA-4 (Nb36) eliminated immunosuppression via blocking CTLA-4-mediated negative co-stimulation in the effector DC-CIK cells. Finally, DC-CIK cells were transferred to kill the tumor cellsBack to article page